Healthcare of Ontario Pension Plan Trust Fund Sells 1,972 Shares of Synopsys, Inc. $SNPS

Healthcare of Ontario Pension Plan Trust Fund cut its stake in shares of Synopsys, Inc. (NASDAQ:SNPSFree Report) by 3.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,255 shares of the semiconductor company’s stock after selling 1,972 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Synopsys were worth $24,683,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. Sankala Group LLC purchased a new stake in Synopsys during the 4th quarter valued at $25,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Synopsys during the fourth quarter worth $28,000. Caitong International Asset Management Co. Ltd bought a new position in Synopsys during the fourth quarter valued at $28,000. Atlas Capital Advisors Inc. bought a new position in Synopsys during the fourth quarter valued at $32,000. Finally, Phillip James Consulting Co. purchased a new stake in shares of Synopsys in the fourth quarter valued at $36,000. 85.47% of the stock is owned by institutional investors.

Insider Transactions at Synopsys

In other news, CEO Sassine Ghazi sold 14,603 shares of Synopsys stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $458.96, for a total transaction of $6,702,192.88. Following the completion of the sale, the chief executive officer owned 75,020 shares of the company’s stock, valued at approximately $34,431,179.20. The trade was a 16.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Shelagh Glaser sold 3,394 shares of the stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $450.02, for a total value of $1,527,367.88. Following the completion of the transaction, the chief financial officer directly owned 14,358 shares in the company, valued at approximately $6,461,387.16. This trade represents a 19.12% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.56% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on SNPS. BNP Paribas Exane raised their target price on shares of Synopsys from $425.00 to $450.00 and gave the stock an “underperform” rating in a report on Thursday, May 28th. Wells Fargo & Company upped their price target on shares of Synopsys from $505.00 to $535.00 and gave the company an “equal weight” rating in a report on Thursday, May 28th. Stifel Nicolaus raised their price objective on shares of Synopsys from $550.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Morgan Stanley raised their price objective on shares of Synopsys from $480.00 to $525.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 28th. Finally, KeyCorp restated an “overweight” rating on shares of Synopsys in a research report on Thursday, May 28th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $570.06.

Read Our Latest Analysis on SNPS

Synopsys Price Performance

Shares of SNPS opened at $373.47 on Monday. The firm has a market capitalization of $71.51 billion, a P/E ratio of 86.45, a P/E/G ratio of 2.19 and a beta of 1.22. Synopsys, Inc. has a 12-month low of $366.00 and a 12-month high of $651.73. The company has a current ratio of 1.43, a quick ratio of 1.32 and a debt-to-equity ratio of 0.33. The firm has a fifty day moving average price of $456.13 and a 200-day moving average price of $454.98.

Synopsys (NASDAQ:SNPSGet Free Report) last posted its quarterly earnings results on Wednesday, May 27th. The semiconductor company reported $3.35 EPS for the quarter, topping analysts’ consensus estimates of $3.15 by $0.20. Synopsys had a net margin of 8.91% and a return on equity of 5.83%. The firm had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.25 billion. During the same period in the prior year, the business posted $3.67 earnings per share. The business’s revenue for the quarter was up 41.9% on a year-over-year basis. Synopsys has set its FY 2026 guidance at 14.720-14.800 EPS and its Q3 2026 guidance at 3.630-3.690 EPS. Equities research analysts expect that Synopsys, Inc. will post 10.65 earnings per share for the current year.

About Synopsys

(Free Report)

Synopsys, Inc is a leading provider of electronic design automation (EDA) software and semiconductor intellectual property (IP) used to design, verify and manufacture integrated circuits and complex systems-on-chip (SoCs). Its product portfolio spans tools and technologies for front‑end design and synthesis, simulation and verification, physical implementation and signoff, and design-for-manufacturability, enabling chip designers to move from architecture through tape‑out.

In addition to core EDA offerings, Synopsys supplies a broad set of semiconductor IP building blocks — such as interface, memory and analog/mixed-signal cores — that customers integrate into SoCs to accelerate development.

See Also

Institutional Ownership by Quarter for Synopsys (NASDAQ:SNPS)

Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.